{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:44:56Z","timestamp":1771667096887,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["30870850, 81071002, 81371386"],"award-info":[{"award-number":["30870850, 81071002, 81371386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinic Study of 5010 Plan, Sun Yat-Sen University","award":["2010003"],"award-info":[{"award-number":["2010003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00415-015-7944-8","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T07:47:53Z","timestamp":1446104873000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study"],"prefix":"10.1007","volume":"263","author":[{"given":"Pei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyi","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"7944_CR1","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","volume":"63","author":"J Rowin","year":"2004","unstructured":"Rowin J, Meriggioli MN, Tuzun E, Leurgans S, Christadoss P (2004) Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63:2390\u20132392","journal-title":"Neurology"},{"key":"7944_CR2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","volume":"64","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, Cervera C, Armengol M (2005) Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64:1641\u20131643","journal-title":"Neurology"},{"key":"7944_CR3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","volume":"20","author":"N Kawaguchi","year":"2004","unstructured":"Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T (2004) Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20:1269\u20131273","journal-title":"Curr Med Res Opin"},{"key":"7944_CR4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","volume":"47","author":"A Nagaishi","year":"2008","unstructured":"Nagaishi A, Yukitake M, Kuroda Y (2008) Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med 47:731\u2013736","journal-title":"Intern Med"},{"key":"7944_CR5","unstructured":"Griffin R, Levine T, Mozaffar T, Nowak R, Pulley M, Dimachkie M, Nicolle M (2015) Efficacy and safety of IGIV-C in corticosteroid dependent patients with generalized myasthenia gravis. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02473965"},{"key":"7944_CR6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719\u2013724","journal-title":"N Engl J Med"},{"key":"7944_CR7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"7944_CR8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43:428\u2013435","journal-title":"Autoimmunity"},{"key":"7944_CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490","journal-title":"Lancet Neurol"},{"key":"7944_CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"7944_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01796261","volume":"44","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT (1995) Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44:317\u2013322","journal-title":"Inflamm Res"},{"key":"7944_CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293\u20131303","journal-title":"N Engl J Med"},{"key":"7944_CR13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:247\u2013256","journal-title":"Lancet Neurol"},{"key":"7944_CR14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","volume":"66","author":"PW O\u2019Connor","year":"2006","unstructured":"O\u2019Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894\u2013900","journal-title":"Neurology"},{"issue":"4","key":"7944_CR15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0192-0561(95)00009-Q","volume":"17","author":"B Vidic-Dankovic","year":"1995","unstructured":"Vidic-Dankovic B, Kosec D, Damjanovic M, Apostolski S, Isakovic K, Bartlett RR (1995) Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 17(4):273\u2013281","journal-title":"Int J Immunopharmacol"},{"key":"7944_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological S (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893\u2013902","journal-title":"Eur J Neurol"},{"key":"7944_CR17","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131:1940\u20131952","journal-title":"Brain"},{"key":"7944_CR18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","volume":"1275","author":"J Cossins","year":"2012","unstructured":"Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S, Jacobson L, Leite MI, Waters P, Vincent A, Beeson D (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275:123\u2013128","journal-title":"Ann N Y Acad Sci"},{"key":"7944_CR19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mus.21713","volume":"42","author":"TM Burns","year":"2010","unstructured":"Burns TM (2010) History of outcome measures for myasthenia gravis. Muscle Nerve 42:5\u201313","journal-title":"Muscle Nerve"},{"key":"7944_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56:97\u201399","journal-title":"Neurology"},{"key":"7944_CR21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/rheumatology\/keh168","volume":"43","author":"G Poor","year":"2004","unstructured":"Poor G, Strand V, Leflunomide Multinational Study G (2004) Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatol (Oxford) 43:744\u2013749","journal-title":"Rheumatol (Oxford)"},{"key":"7944_CR22","first-page":"21","volume":"71","author":"PL Riel van","year":"2004","unstructured":"van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, Breedveld FC (2004) Leflunomide: a manageable safety profile. J Rheumatol Suppl 71:21\u201324","journal-title":"J Rheumatol Suppl"},{"key":"7944_CR23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","volume":"32","author":"N Alcorn","year":"2009","unstructured":"Alcorn N, Saunders S, Madhok R (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32:1123\u20131134","journal-title":"Drug Saf"},{"key":"7944_CR24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14740338.2013.798299","volume":"12","author":"HI Keen","year":"2013","unstructured":"Keen HI, Conaghan PG, Tett SE (2013) Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf 12:581\u2013588","journal-title":"Expert Opin Drug Saf"},{"key":"7944_CR25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400\u2013406","journal-title":"Neurology"},{"key":"7944_CR26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"The Muscle Study Group","year":"2008","unstructured":"The Muscle Study Group (2008) A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71:394\u2013399","journal-title":"Neurology"},{"key":"7944_CR27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1196\/annals.1405.031","volume":"1132","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Siddiqi ZA (2008) Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci 1132:249\u2013253","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-015-7944-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7944-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:22:57Z","timestamp":1559056977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-015-7944-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["7944"],"URL":"https:\/\/doi.org\/10.1007\/s00415-015-7944-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]}}}